While the International Myeloma Working Group (IMWG) Index was validated in scoring patients with newly diagnosed multiple myeloma, its relevance for patients with relapsed or refractory multiple myeloma was uncertain. Therefore, Fabio Efficace, PhD, and a team of researchers investigated IMWG frailty scoring in patients with previously treated disease. Their study, presented at the 2021 American Society of Hematology Annual Meeting and Exposition, reported that the IMWG was able to identify distinct patient-reported health-related quality of life (HRQOL) profiles in relapsed/refractory disease, as well. ...
ASH 2021 Conference: Focus on Multiple Myeloma
Advertisement
The findings report results from 24 months of maintenance therapy and were presented at the ASH Annual Meeting 2021.
This is according to findings from a phase III study presented during the 2021 ASH Annual Meeting.
This marks the first time a study identified epidemiological and clinical characteristics of SMM in a general population.
Updates from this trial were presented at the 63rd American Society of Hematology Annual Meeting & Exhibition.
Researchers explored whether screening for MGUS could increase the frequency of patients with MM being diagnosed.
Researchers evaluated real-world data on DVd for treatment of patients with relapsed or refractory multiple myeloma.
Advertisement
